跳到正文
Sumanta K. Pal, MD, FASCO· @montypal · X·· 2 天前评分90

INTERPATH-001

正文 · 原文

Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @tompowles1, #DeLLphi-305 by @sands_jacob & #DASLHiCaP by @niazi_Dr7. A terrific slate of discussants as well, incl @StephenVLiu (one of the most talented orators in our field, IMHO), @MichvdHeijden, @Silke_Gillessen & more. Hats off to @YJanjigianMD, @FAndreMD, @Prof_Nadia_H & #DrJamesLarkin for assembling a powerhouse program! @OncoAlert

875 浏览 · 25 赞 · 7 转发 · 0 回复

会议摘要
LBA1按 Presidential Symposium I 对上

INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)

https://esmocongress.esmo.org

来源:Sumanta K. Pal, MD, FASCO · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org